LOGIN  |  REGISTER
Assertio
Compass Therapeutics

Brookdale Senior Living Reports December 2024 Occupancy

January 09, 2025 | Last Trade: US$4.88 0.17 -3.37

NASHVILLE, Tenn., Jan. 9, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) reported today its consolidated occupancy for December 2024.

December 2024 Observations:

  • Supported by favorable move-in and move-out levels, December weighted average occupancy increased 100 basis points year-over-year, from 78.3% in 2023 to 79.3% in 2024.
  • Fourth quarter 2024 weighted average occupancy also increased 100 basis points compared to the prior year quarter.
  • Sequentially, fourth quarter 2024 weighted average occupancy increased 50 basis points compared to the third quarter, exceeding normal pre-pandemic seasonality for this period.
  • Fourth quarter 2024 move-in volume surpassed the prior year and exceeded the pre-pandemic average for this period by 8%.

About Brookdale Senior Living 

Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. The Company is committed to its mission of enriching the lives of the people it serves with compassion, respect, excellence, and integrity. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities. Through its comprehensive network, Brookdale helps to provide seniors with care, connection, and services in an environment that feels like home. The Company's expertise in healthcare, hospitality, and real estate provides residents with opportunities to improve wellness, pursue passions, make new friends, and stay connected with loved ones. Brookdale, through its affiliates, operates and manages 647 communities in 41 states as of December 31, 2024, with the ability to serve approximately 58,000 residents. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit brookdale.com or connect with Brookdale on Facebook or YouTube.

 

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page